Enzalutamide in Patients With High-risk Prostate Cancer
Status:
Completed
Trial end date:
2017-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how long it takes for prostate cancer to come back in
patients who have had surgery to remove their prostate gland (radical prostatectomy), while
being treated with enzalutamide (formerly known as MDV3100).
Enzalutamide is known as an androgen-receptor signaling inhibitor, which means that it blocks
activity of the male hormone, testosterone. Most prostate cancers are dependent on
testosterone for growth. In this study, patients will take enzalutamide after surgery to see
if it keeps their cancer from coming back.